8-KShareholder MattersExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (May 23, 2023)

Filed May 23, 2023For Securities:ALNY

Summary

This 8-K filing from Alnylam Pharmaceuticals, Inc. details the outcomes of their Annual Meeting of Stockholders held on May 18, 2023. The key takeaways for investors are the overwhelmingly positive shareholder support for the company's board of directors, executive compensation, and auditor ratification. All proposed director nominees received substantial 'for' votes, indicating shareholder confidence in the current leadership. Furthermore, shareholders approved executive compensation in a non-binding vote and recommended an annual frequency for such votes, aligning with management's intent. The ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2023 also received strong endorsement. These results suggest a stable governance environment and shareholder alignment with the company's strategic direction and financial oversight, which are crucial factors for investor confidence and long-term value creation.

Key Highlights

  • 1All four nominated Class I directors were re-elected with significant 'Votes For' shareholder approval.
  • 2Shareholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers with strong support.
  • 3A substantial majority of shareholders recommended an annual frequency for advisory votes on executive compensation.
  • 4The appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2023 was ratified by shareholders with overwhelming approval.
  • 5The voting outcomes demonstrate high levels of shareholder confidence in the company's board and governance.
  • 6The company intends to hold advisory votes on executive compensation annually until the next required vote on frequency.

Frequently Asked Questions

The main outcomes include the re-election of four Class I directors, the approval of executive compensation in a non-binding vote, a recommendation for annual advisory votes on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2023. All these proposals received strong shareholder support.

Shareholders re-elected all four nominated Class I directors, Michael W. Bonney, Yvonne L. Greenstreet, MBChB, Phillip A. Sharp, Ph.D., and Elliott Sigal, M.D., Ph.D., with a significant majority of 'Votes For' and a low number of 'Votes Against' or abstentions.

The company's stockholders recommended, in a non-binding advisory vote, a frequency of 'One Year' for future advisory votes on the compensation of named executive officers. Alnylam Pharmaceuticals currently intends to hold these advisory votes every year.

No, there was no significant opposition. All key proposals, including director elections, executive compensation approval, frequency of compensation votes, and auditor ratification, received substantial 'Votes For' from shareholders, indicating widespread agreement.